While SGLT2-i and GLP-1RA may offer additive or synergistic benefits in reducing BP and cardiovascular risk, current guidelines do not support their role as first-line antihypertensive agents or early adjunctive therapies over established agents such as thiazide diuretics, renin-angiotensin system (RAS) inhibitors, or calcium channel blockers (CCBs)
Stability at room temperature is worse than vendors admit
As a clinician, it is your job to educate your patients and ensure healthy, safe, and affordable use of these magic weight loss drugs
Consultation Fee: $99 Provider evaluation required Telehealth available throughout South Florida People researching BPC-157 are often interested in recovery support, active lifestyle wellness, healthy aging, and overall wellness optimization
Thats why a treatment that works for someone else may not work for you
When rules are harmful, discriminating and ridiculous they need to be changed